229 related articles for article (PubMed ID: 21068389)
21. Thymidine phosphorylase (platelet-derived endothelial cell growth factor) as a target for capecitabine: from biology to the bedside.
Ranieri G; Roccaro AM; Vacca A; Ribatti D
Recent Pat Anticancer Drug Discov; 2006 Jun; 1(2):171-83. PubMed ID: 18221035
[TBL] [Abstract][Full Text] [Related]
22. Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabine.
Uchida K; Danenberg PV; Danenberg KD; Grem JL
BMC Cancer; 2008 Dec; 8():386. PubMed ID: 19105824
[TBL] [Abstract][Full Text] [Related]
23. Angiogenesis, thymidine phosphorylase, and resistance of squamous cell head and neck cancer to cytotoxic and radiation therapy.
Koukourakis MI; Giatromanolaki A; Fountzilas G; Sivridis E; Gatter KC; Harris AL
Clin Cancer Res; 2000 Feb; 6(2):381-9. PubMed ID: 10690514
[TBL] [Abstract][Full Text] [Related]
24. Prognostication of pancreatic adenocarcinoma by expression of thymidine phosphorylase/dihydropyrimidine dehydrogenase ratio and its correlation with survival.
Saif MW; Hashmi S; Bell D; Diasio RB
Expert Opin Drug Saf; 2009 Sep; 8(5):507-14. PubMed ID: 19663627
[TBL] [Abstract][Full Text] [Related]
25. Thymidine phosphorylase expression in tumour cells and tumour response to capecitabine plus docetaxel chemotherapy in non-small cell lung cancer.
Han JY; Hong EK; Lee SY; Yoon SM; Lee DH; Lee JS
J Clin Pathol; 2005 Jun; 58(6):650-4. PubMed ID: 15917420
[TBL] [Abstract][Full Text] [Related]
26. Expression of thymidine phosphorylase and dihydropyrimidine dehydrogenase in human breast carcinoma cells and tissues.
Loo WT; Chow LW; Suzuki T; Ono K; Ishida T; Hirakawa H; Ohuchi N; Sasano H
Anticancer Res; 2009 Jul; 29(7):2525-30. PubMed ID: 19596923
[TBL] [Abstract][Full Text] [Related]
27. Thymidine phosphorylase and dihydropyrimidine dehydrogenase levels in primary colorectal cancer show a relationship to clinical effects of 5'-deoxy-5-fluorouridine as adjuvant chemotherapy.
Nishimura G; Terada I; Kobayashi T; Ninomiya I; Kitagawa H; Fushida S; Fujimura T; Kayahara M; Shimizu K; Ohta T; Miwa K
Oncol Rep; 2002; 9(3):479-82. PubMed ID: 11956613
[TBL] [Abstract][Full Text] [Related]
28. Thymidine phosphorylase (TP) activation: convenience through innovation.
Van Cutsem E; Cunningham D; Hoff PM; Maroun J
Oncologist; 2001; 6 Suppl 4():1-2. PubMed ID: 11585967
[No Abstract] [Full Text] [Related]
29. Predictive markers of capecitabine sensitivity identified from the expression profile of pyrimidine nucleoside-metabolizing enzymes.
Yasuno H; Kurasawa M; Yanagisawa M; Sato Y; Harada N; Mori K
Oncol Rep; 2013 Feb; 29(2):451-8. PubMed ID: 23229803
[TBL] [Abstract][Full Text] [Related]
30. Thymidine phosphorylase in cancer aggressiveness and chemoresistance.
Furukawa T; Tabata S; Yamamoto M; Kawahara K; Shinsato Y; Minami K; Shimokawa M; Akiyama SI
Pharmacol Res; 2018 Jun; 132():15-20. PubMed ID: 29604437
[TBL] [Abstract][Full Text] [Related]
31. Capecitabine: a review.
Walko CM; Lindley C
Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
[TBL] [Abstract][Full Text] [Related]
32. Positive interaction between lapatinib and capecitabine in human breast cancer models: study of molecular determinants.
Chefrour M; Milano G; Formento P; Giacometti S; Denden A; Renée N; Iliadis A; Fischel JL; Ciccolini J
Fundam Clin Pharmacol; 2012 Aug; 26(4):530-7. PubMed ID: 21623901
[TBL] [Abstract][Full Text] [Related]
33. Induction of thymidine phosphorylase expression by Taxol does not enhance Furtulon sensitivity in a cisplatin-resistant human ovarian carcinoma cell line.
Hata K; Osaki M; Kanasaki H; Nakayama K; Fujiwaki R; Ito H; Miyazaki K
Anticancer Res; 2003; 23(2B):1525-31. PubMed ID: 12820419
[TBL] [Abstract][Full Text] [Related]
34. Thymidine phosphorylase is both a therapeutic and a suicide gene in a murine model of mitochondrial neurogastrointestinal encephalomyopathy.
López-Estévez S; Ferrer G; Torres-Torronteras J; Mansilla MJ; Casacuberta-Serra S; Martorell L; Hirano M; Martí R; Barquinero J
Gene Ther; 2014 Jul; 21(7):673-81. PubMed ID: 24807807
[TBL] [Abstract][Full Text] [Related]
35. Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome.
Saif MW; Eloubeidi MA; Russo S; Steg A; Thornton J; Fiveash J; Carpenter M; Blanquicett C; Diasio RB; Johnson MR
J Clin Oncol; 2005 Dec; 23(34):8679-87. PubMed ID: 16314628
[TBL] [Abstract][Full Text] [Related]
36. 5-Ethoxy-2'-deoxyuridine, a novel substrate for thymidine phosphorylase, potentiates the antitumor activity of 5-fluorouracil when used in combination with interferon, an inducer of thymidine phosphorylase expression.
Schwartz EL; Baptiste N; Megati S; Wadler S; Otter BA
Cancer Res; 1995 Aug; 55(16):3543-50. PubMed ID: 7627962
[TBL] [Abstract][Full Text] [Related]
37. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients.
Schüller J; Cassidy J; Dumont E; Roos B; Durston S; Banken L; Utoh M; Mori K; Weidekamm E; Reigner B
Cancer Chemother Pharmacol; 2000; 45(4):291-7. PubMed ID: 10755317
[TBL] [Abstract][Full Text] [Related]
38. The role of thymidine phosphorylase in the induction of early growth response protein-1 and thrombospondin-1 by 5-fluorouracil in human cancer carcinoma cells.
Matsushita S; Ikeda R; Nishizawa Y; Che XF; Furukawa T; Miyadera K; Tabata S; Ushiyama M; Tajitsu Y; Yamamoto M; Takeda Y; Minami K; Mataki H; Kanzaki T; Yamada K; Kanekura T; Akiyama S
Int J Oncol; 2010 May; 36(5):1193-200. PubMed ID: 20372793
[TBL] [Abstract][Full Text] [Related]
39. Interferon-α enhances 5'-deoxy-5-fluorouridine-induced apoptosis by ERK-dependant upregulation of thymidine phosphorylase.
Zhu Y; Xu L; Fan Y; Li C; Zhang Y; Zheng H; Hou K; Qu X; Liu Y
Biomed Res Int; 2013; 2013():132793. PubMed ID: 24027750
[TBL] [Abstract][Full Text] [Related]
40. Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer.
Aprile G; Mazzer M; Moroso S; Puglisi F
Anticancer Drugs; 2009 Apr; 20(4):217-29. PubMed ID: 19247178
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
